Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Decibel Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Laurence Reid

İcra Kurulu Başkanı

US$1.2m

Toplam tazminat

CEO maaş yüzdesi	44.5%
CEO görev süresi	3.8yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2.1yrs
Yönetim Kurulu ortalama görev süresi	2.4yrs

Son yönetim güncellemeleri

Recent updates

Here's Why We're Watching Decibel Therapeutics' (NASDAQ:DBTX) Cash Burn Situation

Aug 10

Is Decibel Therapeutics (NASDAQ:DBTX) In A Good Position To Deliver On Growth Plans?

Feb 07

Decibel stock surges 18% as FDA clears hearing loss gene therapy to enter trial

Oct 17

We Think Decibel Therapeutics (NASDAQ:DBTX) Needs To Drive Business Growth Carefully

Sep 01

Decibel Therapeutics: Gene Therapies For Hearing Loss

Jul 06

CEO Tazminat Analizi

Laurence Reid'un ücretlendirmesi Decibel Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2023	n/a	n/a	-US$63m
Mar 31 2023	n/a	n/a	-US$62m
Dec 31 2022	US$1m	US$548k	-US$63m
Sep 30 2022	n/a	n/a	-US$60m
Jun 30 2022	n/a	n/a	-US$60m
Mar 31 2022	n/a	n/a	-US$55m
Dec 31 2021	US$801k	US$522k	-US$54m
Sep 30 2021	n/a	n/a	US$576k
Jun 30 2021	n/a	n/a	US$7m
Mar 31 2021	n/a	n/a	US$8m
Dec 31 2020	US$4m	US$574k	US$7m

Tazminat ve Piyasa: Laurence 'nin toplam tazminatı ($USD 1.23M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 677.23K ).

Tazminat ve Kazançlar: Laurence şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Laurence Reid (59 yo)

3.8yrs

Görev süresi

US$1,232,276

Tazminat

Dr. Laurence E. Reid, Ph D., serves as President, Chief Executive Officer and until September 25, 2023 served as Director at Decibel Therapeutics, Inc. since January 2020 and served as its consultant since...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Laurence Reid	President & CEO	3.8yrs	US$1.23m	Veri yok
Anna Trask	Executive VP & Chief People Officer	5.8yrs	US$618.23k	0% $ 0
John Lee	Executive VP & Chief Development Officer	7.1yrs	US$733.16k	0% $ 0
M. Liberman	Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Gabriel Corfas	Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Ulrich Müller	Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Albert S. Edge	Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
James Murphy	Interim CFO	less than a year	Veri yok	Veri yok
Elaine Cope	Vice President of Operations	2.1yrs	Veri yok	Veri yok
Geoff Horwitz	VP of Corporate Development & Head of Business Development	less than a year	Veri yok	Veri yok
Vassili Valayannopoulos	VP and Head of Clinical Research & Development	less than a year	Veri yok	Veri yok

2.1yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim: DBTX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
M. Liberman	Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Gabriel Corfas	Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Ulrich Müller	Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Albert S. Edge	Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Glenn Pierce	Member of Scientific Advisory Board	2.4yrs	Veri yok	Veri yok
Constance Cepko	Member of Scientific Advisory Board	2.4yrs	Veri yok	Veri yok
Guangping Gao	Member of Scientific Advisory Board	2.4yrs	Veri yok	Veri yok
Alan Cheng	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
David Ginty	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Michael Greenberg	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Dwight Bergles	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Matthew Kelley	Member of Scientific Advisory Board	2.4yrs	Veri yok	Veri yok

2.4yrs

Ortalama Görev Süresi

68yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: DBTX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.4 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Decibel Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Decibel Therapeutics, Inc. Announces Board Changes

High number of new directors

High number of new directors

Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors

Decibel Therapeutics, Inc. Announces Executive Changes

Decibel Therapeutics, Inc., Annual General Meeting, Jun 17, 2022

Recent updates

Decibel Therapeutics, Inc. Files Form 15

New major risk - Revenue and earnings growth

Decibel Therapeutics, Inc.(NasdaqGS:DBTX) dropped from NASDAQ Composite Index

Decibel Therapeutics, Inc. Announces Board Changes

Decibel Therapeutics, Inc. Announces U.S. Food and Drug Administration Grants Fast Track Designation for DB-OTO

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) entered into a definitive agreement to acquire remaining unknown majority stake in Decibel Therapeutics, Inc. (NasdaqGS:DBTX) from a group of shareholders for approximately $100 million.

Here's Why We're Watching Decibel Therapeutics' (NASDAQ:DBTX) Cash Burn Situation

Price target increased by 13% to US$15.33

Consensus EPS estimates upgraded to US$1.89 loss

Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices to Initiate Clinical Development of Lead Gene Therapy Candidate Db-OTO

Price target decreased by 7.4% to US$12.60

Is Decibel Therapeutics (NASDAQ:DBTX) In A Good Position To Deliver On Growth Plans?

PDecibel Therapeutics, Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO

Consensus revenue estimates fall by 25%

High number of new directors

Decibel Therapeutics, Inc. Announces Submission of Clinical Trial Applications for Lead Gene Therapy Candidate Db-Oto

High number of new directors

Price target decreased to US$14.60

Decibel Therapeutics, Inc. Receives Fda Clearance of Ind Application for Db-Oto, A Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss

Decibel stock surges 18% as FDA clears hearing loss gene therapy to enter trial

Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors

Decibel Therapeutics Announces Submission of Investigational New Drug (IND) Application for Lead Gene Therapy Candidate DB-OTO

Decibel Therapeutics, Inc. Announces Executive Changes

We Think Decibel Therapeutics (NASDAQ:DBTX) Needs To Drive Business Growth Carefully

Price target decreased to US$15.40

Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy

Price target decreased to US$14.75

Consensus forecasts updated

Decibel Therapeutics, Inc., Annual General Meeting, Jun 17, 2022

Price target decreased to US$17.00

Less than half of directors are independent

Price target decreased to US$21.33

Decibel Therapeutics Announces the Presentation of Preclinical Data on Lead Gene Therapy Product Candidate, DB-OTO and Preclinical Data Highlighting the Identification of Proprietary

Less than half of directors are independent

Chief People notifies of intention to sell stock

President recently bought US$76k worth of stock

Vice President of Finance & Principal Accounting Officer Ronald Vigliotta has left the company

Investor sentiment improved over the past week

Consensus revenue estimates fall to US$2.08m

Investor sentiment deteriorated over the past week

Decibel Therapeutics: Gene Therapies For Hearing Loss

Decibel Therapeutics, Inc.(NasdaqGS:DBTX) dropped from Russell Microcap Growth Index

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Decibel Therapeutics, Inc. Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations

Decibel Therapeutics, Inc. has completed an IPO in the amount of $127.116 million.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş